Tags

Type your tag names separated by a space and hit enter

Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
J Cell Physiol. 2005 Nov; 205(2):246-52.JC

Abstract

Analysis of peripheral blood (>85% CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia (B-CLL), showed that surface TNF-related apoptosis inducing ligand (TRAIL) was expressed in all samples and at higher levels with respect to unfractionated lymphocytes and purified CD19+ B cells, obtained from 15 normal blood donors. Of note, in a subset of B-CLL samples, the addition to B-CLL cultures of a TRAIL-R1-Fc chimera, which binds at high affinity to surface TRAIL, significantly decreased the percentage of viable cells with respect to untreated control B-CLL cells, suggesting that surface TRAIL may play an unexpected role in promoting B-CLL cell survival. In spite of the majority of B-CLL lymphocytes expressed variable surface levels of "death receptors" TRAIL-R1 and TRAIL-R2, the addition in culture of recombinant TRAIL increased (>20% vs. controls) the degree of spontaneous apoptosis in only 11/44 of the B-CLL samples, had no effect in 19/44, while it significantly increased leukemic cell survival in 14/44. Taken together, these findings suggest that an aberrant expression of TRAIL might contribute to the pathogenesis of B-CLL by promoting the survival in a subset of B-CLL cells.

Authors+Show Affiliations

Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, Ferrara, Italy. secchier@mail.umbi.umd.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15887227

Citation

Secchiero, Paola, et al. "Aberrant Expression of TRAIL in B Chronic Lymphocytic Leukemia (B-CLL) Cells." Journal of Cellular Physiology, vol. 205, no. 2, 2005, pp. 246-52.
Secchiero P, Tiribelli M, Barbarotto E, et al. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol. 2005;205(2):246-52.
Secchiero, P., Tiribelli, M., Barbarotto, E., Celeghini, C., Michelutti, A., Masolini, P., Fanin, R., & Zauli, G. (2005). Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology, 205(2), 246-52.
Secchiero P, et al. Aberrant Expression of TRAIL in B Chronic Lymphocytic Leukemia (B-CLL) Cells. J Cell Physiol. 2005;205(2):246-52. PubMed PMID: 15887227.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. AU - Secchiero,Paola, AU - Tiribelli,Mario, AU - Barbarotto,Elisa, AU - Celeghini,Claudio, AU - Michelutti,Angela, AU - Masolini,Paola, AU - Fanin,Renato, AU - Zauli,Giorgio, PY - 2005/5/12/pubmed PY - 2005/12/24/medline PY - 2005/5/12/entrez SP - 246 EP - 52 JF - Journal of cellular physiology JO - J Cell Physiol VL - 205 IS - 2 N2 - Analysis of peripheral blood (>85% CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia (B-CLL), showed that surface TNF-related apoptosis inducing ligand (TRAIL) was expressed in all samples and at higher levels with respect to unfractionated lymphocytes and purified CD19+ B cells, obtained from 15 normal blood donors. Of note, in a subset of B-CLL samples, the addition to B-CLL cultures of a TRAIL-R1-Fc chimera, which binds at high affinity to surface TRAIL, significantly decreased the percentage of viable cells with respect to untreated control B-CLL cells, suggesting that surface TRAIL may play an unexpected role in promoting B-CLL cell survival. In spite of the majority of B-CLL lymphocytes expressed variable surface levels of "death receptors" TRAIL-R1 and TRAIL-R2, the addition in culture of recombinant TRAIL increased (>20% vs. controls) the degree of spontaneous apoptosis in only 11/44 of the B-CLL samples, had no effect in 19/44, while it significantly increased leukemic cell survival in 14/44. Taken together, these findings suggest that an aberrant expression of TRAIL might contribute to the pathogenesis of B-CLL by promoting the survival in a subset of B-CLL cells. SN - 0021-9541 UR - https://www.unboundmedicine.com/medline/citation/15887227/Aberrant_expression_of_TRAIL_in_B_chronic_lymphocytic_leukemia__B_CLL__cells_ L2 - https://doi.org/10.1002/jcp.20392 DB - PRIME DP - Unbound Medicine ER -